Comparison of the clinical efficacy of salbutamol with jet and mesh nebulizers in asthmatic children

Comparison of the clinical efficacy of salbutamol with jet and mesh nebulizers in asthmatic children - Mesh and jet nebulizers in asthma.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030683

Enrollment

100

Registered

2018-01-05

Start date

2003-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthmatic children

Interventions

By mesh type and jet type nebulizer, salbutamol inhalation Age and Salbutamol

&lt

2 years 0.1ml, &gt

2 years 0.2 ml. From Oct 2003 to Jan 2004.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Child patients with asthma attack on Murayama Pediatrics.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
This study included 88 patients <6 years of age who were treated for mild asthma attacks at Maruyama Pediatric Clinic between October 2003 and January 2004,	—

Secondary

Measure	Time frame
After informed consent, patients were randomly assigned to receive treatment with either a mesh- or jet-type electronic nebulizer. For children <2 years old (n=37), a total volume of 1 mL was used, comprising 0.1 mL of salbutamol inhalation solution and 0.9 mL of saline. For children 2 years old (n=51), the total volume was 1 mL, comprising 0.2 mL of salbutamol inhalation solution and 0.8 mL of saline. Pre and post clinical symptom score, Saturation and Heart rate were examined.	—

Measure

Time frame

After informed consent, patients were randomly assigned to receive treatment with either a mesh- or jet-type electronic nebulizer. For children <2 years old (n=37), a total volume of 1 mL was used, comprising 0.1 mL of salbutamol inhalation solution and 0.9 mL of saline. For children 2 years old (n=51), the total volume was 1 mL, comprising 0.2 mL of salbutamol inhalation solution and 0.8 mL of saline. Pre and post clinical symptom score, Saturation and Heart rate were examined.

—

Countries

Japan

Contacts

Public ContactNorihide Murayama

Murayama Pediatrics Pediatrics

norihide99@yahoo.co.jp06-6790-8835

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026